Pharma BD Deal Intelligence
Bristol-Myers Squibb's $430M cash-plus-$75M-earnout buy of Adnexus landed over 100 issued and pending patents and made the Adnectins platform a core BMS biologics engine, though its headline Phase I asset, Angiocept, went no further in the sourced record.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Definitive agreement under which BMS acquires all outstanding Adnexus shares for $430M gross / $415M net; Adnectins biologics platform a core strategic…
Adnexus adopted monobody technology commercially as Adnectins; BMS acquired Adnexus in 2007, making the Adnectin scaffold a core BMS biologics platform.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$430M cash + up to $75M earnout. Adnectins biologics platform; Angiocept Phase I. Source: SEC, Fierce Biotech, WilmerHale.
15K US cases/yr
Glioblastoma (GBM) is the most aggressive primary brain tumor, with a median survival of 10-15 months despite surgery, radiation, and temozolomide. Anti-angiogenic strategies aim to starve tumors by blocking VEGF/VEGFR-2 signaling, but durable benefit has remained elusive. Adnexus' lead Adnectin Angiocept (CT-322) was a VEGFR-2 antagonist positioned in this difficult-to-treat space.
At deal time (2007), the anti-angiogenic franchise was dominated by Genentech/Roche's bevacizumab (Avastin), an anti-VEGF-A monoclonal antibody, with sunitinib (Sutent) and sorafenib (Nexavar) covering VEGFR-targeted small molecules. BMS's interest in Adnexus was less about Angiocept's standalone potential and more about owning the Adnectins/PROfusion platform — a fibronectin-domain-based scaffold positioned as a non-antibody alternative to mAbs that could be engineered faster and more flexibly. Angiocept (CT-322/pegdinetanib) ultimately progressed into Phase 2 in recurrent glioblastoma and showed early activity at 1 mg/kg IV weekly, but never advanced to approval and the asset was effectively shelved. The deal mattered strategically because it gave BMS a proprietary biologics format orthogonal to its Medarex/Imclone antibody assets, supporting its post-Plavix biologics pivot. The acquisition's lasting legacy is the Adnectin platform itself — later spawning multiple BMS pipeline candidates — rather than the lead asset.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Adnexus Therapeutics Inc. (this deal) | 2007 | $430M | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |